Brokerages expect that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will post ($0.12) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Vanda Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.08). Vanda Pharmaceuticals reported earnings of ($0.01) per share during the same quarter last year, which would indicate a negative year over year growth rate of 1,100%. The firm is scheduled to report its next earnings results on Wednesday, February 21st.
According to Zacks, analysts expect that Vanda Pharmaceuticals will report full-year earnings of ($0.42) per share for the current financial year, with EPS estimates ranging from ($0.45) to ($0.39). For the next fiscal year, analysts forecast that the business will post earnings of ($0.17) per share, with EPS estimates ranging from ($0.34) to $0.04. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that cover Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The business had revenue of $41.30 million during the quarter, compared to analysts’ expectations of $43.90 million. During the same period last year, the business earned ($0.01) earnings per share. The firm’s revenue was up 7.3% on a year-over-year basis.
Several equities research analysts have issued reports on the company. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 5th. Piper Jaffray Companies raised their price target on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Thursday, September 14th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. Jefferies Group LLC reaffirmed a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. Finally, BidaskClub raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $21.50.
Shares of Vanda Pharmaceuticals (VNDA) traded up $0.40 during trading on Friday, reaching $13.25. The company’s stock had a trading volume of 379,600 shares, compared to its average volume of 557,111. Vanda Pharmaceuticals has a fifty-two week low of $11.90 and a fifty-two week high of $18.99.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Cubist Systematic Strategies LLC lifted its holdings in shares of Vanda Pharmaceuticals by 221.3% during the third quarter. Cubist Systematic Strategies LLC now owns 25,387 shares of the biopharmaceutical company’s stock worth $454,000 after buying an additional 17,485 shares in the last quarter. University of Notre Dame DU Lac acquired a new stake in shares of Vanda Pharmaceuticals during the third quarter worth $2,824,000. Schwab Charles Investment Management Inc. lifted its holdings in shares of Vanda Pharmaceuticals by 2.5% during the third quarter. Schwab Charles Investment Management Inc. now owns 472,516 shares of the biopharmaceutical company’s stock worth $8,459,000 after buying an additional 11,647 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Vanda Pharmaceuticals by 112.2% during the third quarter. Wells Fargo & Company MN now owns 151,693 shares of the biopharmaceutical company’s stock worth $2,715,000 after buying an additional 80,209 shares in the last quarter. Finally, Cadence Capital Management LLC acquired a new stake in shares of Vanda Pharmaceuticals during the third quarter worth $1,121,000. 87.28% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Vanda Pharmaceuticals Inc. (VNDA) Expected to Post Earnings of -$0.12 Per Share” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/11/17/vanda-pharmaceuticals-inc-vnda-expected-to-post-earnings-of-0-12-per-share.html.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.